Gilead Sciences (NASDAQ:GILD) Issues Quarterly Earnings Results

Gilead Sciences (NASDAQ:GILD) released its earnings results on Thursday. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12, Zacks reports. Gilead Sciences had a return on equity of 49.45% and a net margin of 30.99%.The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the previous year, the company posted $1.81 earnings per share. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences updated its FY 2026 guidance to -1.050–0.650 EPS.

Here are the key takeaways from Gilead Sciences’ conference call:

• Gilead raised 2026 revenue guidance by $400 million after a strong Q1, with updated 2026 base business sales of $29.4B–$29.8B and total product sales now expected at $30.0B–$30.4B, reflecting broad commercial execution.
• The U.S. PrEP franchise accelerated (PrEP sales +87% YoY) driven by YES2GO’s rapid launch (Q1 sequential growth +72%), and Gilead raised YES2GO 2026 guidance to ~$1 billion with ~95% U.S. coverage and high $0 copay access.
• Key HIV pipeline catalysts remain on track: the once-daily bictegravir+lenacapavir (BIC/LEN) is under priority FDA review with a decision expected in August, and multiple long-acting oral/injectable programs could support new launches through 2033.
• Gilead closed Arcellx and is acquiring Ouro Medicines and Tubulis, and upfront acquired IPR&D and transaction financing (~$11.5B in upfronts and ~$9.50/share impact) drive a 2026 non?GAAP EPS range of $(1.05)–$(0.65) and an unusually high effective tax rate (140%–190%).
• Oncology and cell therapy momentum continued: Trodelvy sales were +37% YoY with potential first?line metastatic TNBC regulatory decisions in H2 2026, and anito?cel (Arcellx) has a December PDUFA with revenue expected to begin in early 2027.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $131.33 on Friday. The stock has a 50-day simple moving average of $139.59 and a two-hundred day simple moving average of $132.87. Gilead Sciences has a 52-week low of $96.18 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The firm has a market capitalization of $163.01 billion, a PE ratio of 17.89, a P/E/G ratio of 1.77 and a beta of 0.31.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s payout ratio is currently 48.45%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the chief financial officer owned 176,191 shares of the company’s stock, valued at approximately $24,835,883.36. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the sale, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at $81,702,353.72. This represents a 1.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 63,000 shares of company stock valued at $9,238,250. Company insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

A number of hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its stake in Gilead Sciences by 4.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock valued at $3,399,734,000 after acquiring an additional 1,195,269 shares in the last quarter. Bank of America Corp DE grew its stake in Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after acquiring an additional 3,046,688 shares in the last quarter. Amundi grew its holdings in Gilead Sciences by 25.5% during the 4th quarter. Amundi now owns 9,520,135 shares of the biopharmaceutical company’s stock valued at $1,168,501,000 after buying an additional 1,936,354 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Gilead Sciences by 1.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,006,790 shares of the biopharmaceutical company’s stock worth $982,753,000 after acquiring an additional 75,930 shares during the last quarter. Finally, Raymond James Financial Inc. increased its stake in Gilead Sciences by 50.6% in the 4th quarter. Raymond James Financial Inc. now owns 2,734,917 shares of the biopharmaceutical company’s stock worth $336,007,000 after acquiring an additional 919,106 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on GILD shares. Deutsche Bank Aktiengesellschaft boosted their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Argus boosted their price target on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Rothschild & Co Redburn boosted their price target on Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Bank of America set a $162.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Finally, Daiwa Securities Group upped their price objective on Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $157.50.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Truist Financial reaffirmed its buy rating on Gilead and raised its price target to $157 from $155, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Gilead reported Q1 EPS of $2.03 and revenue of $6.96 billion, both ahead of analyst expectations, supported by HIV and Trodelvy sales growth. Yahoo Finance
• Positive Sentiment: The company raised its Yeztugo 2026 sales guidance to $1 billion from $800 million, signaling stronger-than-expected launch momentum. Yahoo Finance
• Neutral Sentiment: RBC slightly reduced its price target to $122 from $123 and kept a sector perform view, suggesting a more cautious stance but no major change in thesis. Benzinga
• Negative Sentiment: Gilead cut its 2026 EPS guidance to a loss range of -$1.05 to -$0.65, a major deterioration from prior profit expectations, due to acquisition charges and financing costs. Reuters
• Negative Sentiment: Investors also appear concerned that near-term growth is being driven more by older products like Descovy and Biktarvy than by the much-anticipated Yeztugo launch, creating questions about the pace of future growth. Yahoo Finance

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.